Pre-Clinical Research
Filter News
Found 7,957 articles
-
GT Biopharma Announces Positive Preclinical Results For GTB-5550 B7H3 TriKE™
8/3/2021
GT Biopharma, Inc. announced preclinical results for GTB-5550, its B7H3 TriKE™ product candidate as a prospective therapy for the treatment of several different types of cancers.
-
Delix Therapeutics Continues Rapid Growth with Appointment of Chief Medical Officer
8/2/2021
Preclinical neuroscience company Delix Therapeutics (the "Company"), today announced the appointment of Dr. Brigitte Robertson as Chief Medical Officer.
-
Hoth Therapeutics Initiates Preclinical Study of HT-ALZ for Alzheimer's Disease
8/2/2021
Hoth Therapeutics, Inc. announced today that it has initiated its preclinical study utilizing Hoth's HT-ALZ in an animal model.
-
SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study
8/2/2021
SciSparc Ltd. (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain.
-
Topline results from a late-stage trial announced Thursday show Regeneron Pharmaceuticals and Sanofi's Dupixent (dupilumab) significantly reduced itch and hives better than antihistamines alone in biologic-naiïve patients with moderate-to-severe chronic spontaneous urticaria.
-
Oligomerix Presents Preclinical Data Showing Efficacy of Differentiated Approach Targeting Tau in Models of Alzheimer’s Disease and Related Tauopathies
7/30/2021
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the Company presented at the 2021 Alzheimer's Association International Conference (AAIC) in a presentation titled “In vivo validation of therapeutic efficacy of a small molecule lead targeting tau self-association in JNPL3 mice.”
-
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors
7/30/2021
Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the publication of a comprehensive preclinical in vitro and in vivo data package of its innate cell engager AFM24 in mAbs.
-
Karyopharm Announces Dosing of First Patients in Two New Company-Sponsored Clinical Studies in Melanoma and Myelofibrosis
7/28/2021
Karyopharm Therapeutics Inc. announced dosing of the first patients in two new company-sponsored Phase 2 and 1/2 clinical studies evaluating XPOVIO®, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export compound in combination with approved therapies in patients with advanced melanoma and in patients with treatment naïve myelofibrosis.
-
The company announced its Malaria project, part of the “eradicateMalaria” initiative led by the kENUP Foundation.
-
Just as it was beginning to appear safe to return to maskless, pre-pandemic life, the Delta variant of the SARS-CoV-2 virus emerged. It is fast-spreading, more likely to lead to hospitalizations, and accounts for most of the breakout infections among fully vaccinated individuals.
-
Regeneron and AstraZeneca are looking to research, develop, and eventually commercialize a new drug that targets GPR75, the gene associated with obesity.
-
Therapeutic Solutions International Reports Preclinical Efficacy of JadiCell Umbilical Cord Mesenchymal Stem Cells in Animal Model Resembling COVID-19 Delta Variant Associated Lung Pathology
7/27/2021
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today preliminary data demonstrating administration of its universal donor adult stem cell product, JadiCell, reduced pulmonary pathology in an animal model replicating the severe inflammation observed in patients infected with the COVID-19 delta variant.
-
Ipsen Strengthens Its Pre-clinical Oncology Pipeline With an Exclusive Worldwide-collaboration With BAKX Therapeutics Inc. for BKX-001, Targeting the Apoptosis Pathway
7/27/2021
Ipsen (Euronext: IPN; ADR: IPSEY) and BAKX Therapeutics Inc. have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture and commercialize BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
-
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
7/27/2021
Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp.
-
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections
7/26/2021
In June 2021, results from a preclinical study jointly conducted by Antengene, American biopharmaceutical company Karyopharm Therapeutics and University of Georgia College of Veterinary Medicine has been published in a paper titled "selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo", in Antiviral Research, a leading scientific journal in the field of virology.
-
With COVID-19 resurging in the U.S., particularly in states with the lowest vaccination rates, additional news and research about the vaccines and the virus is coming out. Here’s a look.
-
Sigilon Therapeutics Presents Preclinical Data at the 16th International Symposium on MPS and Related Diseases
7/23/2021
Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported results from several ongoing preclinical studies in the rare lysosomal diseases MPS-1, MPS-2, and MPS-6.
-
Companies such as Indoor Biotechnologies in Virginia are leveraging cutting-edge scientific techniques to not only reduce the amount of the protein expressed but completely knock it out.
-
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
7/21/2021
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
-
Preclinical data for its drug candidate, LP-184, reportedly showed over 90 percent efficacy in shrinking pancreatic cancer tumors in mouse models in vitro, in-vivo, and ex-vivo.